Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan (N-003) for Portal Hypertension in Decompensated Cirrhosis
NCT03827200Phase 2Terminated
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in Portal Hypertension (PH) and Cirrhosis, sponsored by Noorik Biopharmaceuticals AG. Primary endpoint: Hepatic Vein Pressure Gradient at 14 days. Started Apr 2019; status: terminated.
02
Drugs
ambrisentan
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on NCT03827200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827200.